Nebicard (Nebivolol Hydrochloride)

Nebivolol, the active ingredient in Nebicard, is a beta blocker presented as an oral tablet for oral use. It is indicated for the management of hypertension in adult patients, helping to lower elevated blood pressure through selective β1‑adrenergic blockade and vasodilatory effects.

GNH USA supplies Nebicard as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide. The company follows EU quality standards and provides batch‑tested product for global distribution.

Nebivolol is a selective β1‑adrenergic antagonist used primarily in the treatment of hypertension.

- Hypertension: reduces systolic and diastolic blood pressure, improving cardiovascular risk profile.

Nebivolol may cause a range of adverse reactions that vary in frequency and severity.

Common Side Effects: - Headache: mild to moderate pain often occurring early in therapy. - Dizziness: sensation of light‑headedness, especially when standing quickly. - Fatigue: generalized tiredness or lack of energy. - Bradycardia: slower than normal heart rate. - Peripheral edema: mild swelling of the ankles or feet.

Serious or Rare Side Effects: - Severe bradycardia: markedly low heart rate requiring medical attention. - Atrioventricular block: impaired electrical conduction through the heart. - Bronchospasm: difficulty breathing, particularly in patients with reactive airway disease. - Allergic reaction: rash, itching, swelling, or anaphylaxis. - Hepatotoxicity: signs of liver injury such as jaundice or elevated enzymes.

When prescribing Nebicard, clinicians should consider several safety aspects.

- Blood pressure monitoring: assess response and adjust dose as needed. - Cardiac function assessment: evaluate for existing conduction abnormalities. - Respiratory caution: avoid in patients with severe asthma or COPD. - Renal impairment: dose may require adjustment in reduced kidney function. - Discontinuation: taper gradually to prevent rebound hypertension. - Store at room temperature: keep in the original container, protect from moisture and direct sunlight.

Nebicard can interact with other medicines, altering its efficacy or safety.

Major Interactions (Avoid): - Other beta blockers: additive bradycardia and hypotension. - Calcium channel blockers (verapamil, diltiazem): increased risk of heart block. - Potent CYP2D6 inhibitors (paroxetine, fluoxetine): elevated nebivolol plasma levels.

Moderate Interactions (Monitor Closely): - Diuretics: may enhance antihypertensive effect, requiring BP monitoring. - NSAIDs: can blunt antihypertensive response. - Antidiabetic agents: may mask hypoglycemia symptoms. - Other CYP2D6 substrates: possible altered metabolism. - Antihypertensive combinations: monitor for excessive blood pressure lowering.